SCHEMBL733215

SCHEMBL733215

CC1=C(CCC(=O)O)C(=O)OC1=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 8/20 0.59
CDC25B P30305 8/20 0.59
CDC25C P30307 6/20 0.59
NPSR1 Q6W5P4 1/20 0.39
ALDH1A1 P00352 2/20 0.38
PKM P14618 1/20 0.38
KEAP1 Q14145 1/20 0.38
FFAR1 O14842 5/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
GAA P10253 2/20 0.35
KDM4E B2RXH2 1/20 0.35
GLA P06280 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35
HSD17B10 Q99714 1/20 0.35
FFAR4 Q5NUL3 2/20 0.34
MAP2K7 O14733 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13964188 0.84 CDC25A (0.42) CDC25ACDC25BCDC25CALDH1A1PKM
SCHEMBL9924710 0.82 CDC25A (0.41) CDC25ACDC25BCDC25CALDH1A1TSHR
SCHEMBL14029275 0.81 CDC25B (0.45) CDC25ACDC25BCDC25CALDH1A1
SCHEMBL18510223 0.81 CDC25A (0.44) CDC25ACDC25BCDC25C
SCHEMBL14029273 0.80 CDC25A (0.69) CDC25ACDC25BCDC25CNPSR1ALDH1A1
SCHEMBL18862049 0.79 CDC25A (0.39) CDC25ACDC25BCDC25CKDM4E
SCHEMBL29433633 0.79 CDC25A (0.41) CDC25ACDC25BCDC25CALDH1A1PKM
SCHEMBL14015504 0.79 CDC25A (0.43) CDC25ACDC25BCDC25C
SCHEMBL9946505 0.78 CDC25A (0.38) CDC25ACDC25BCDC25CALDH1A1KDM4E
SCHEMBL23295801 0.78 FOLH1 (0.44) CDC25ACDC25BCDC25CGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120000803-A Brush-like structure polypeptide drug delivery system and preparation method and application thereof 中国科学院杭州医学研究所 2025-05-16 CN claimed
CN-112979881-B Macromolecules, compositions and methods for enhancing anticancer drug uptake 南开大学 2023-06-27 CN claimed
CN-112979881-A Macromolecule and composition for promoting anticancer drug intake and application thereof in preparing anticancer drugs 南开大学 2021-06-18 CN claimed
CN-109999183-B Nano-clustering enzyme containing hypoxia activated prodrug and preparation method and application thereof 中国科学技术大学 2021-03-09 CN claimed
CN-107951839-B Polyion micelle shielding system with reversible charges and preparation method thereof 中国科学院长春应用化学研究所 2020-05-19 CN claimed
EP-4730479-A2 FLAME-RETARDANT NON-AQUEOUS ELECTROLYTIC SOLUTION AND SECONDARY BATTERY USING SAME Kyoto University (JP) 2026-04-22 EP disclosed
EP-3438208-B1 THERMOPLASTIC RESIN COMPOSITION, CELLULOSE-REINFORCED THERMOPLASTIC RESIN COMPOSITION, METHOD FOR PRODUCING CELLULOSE-REINFORCED THERMOPLASTIC RESIN COMPOSITION, CELLULOSE-REINFORCED RESIN MOLDED ARTICLE, AND METHOD FOR PRODUCING CELLULOSE-REINFORCED RESIN MOLDED ARTICLE FURUKAWA ELECTRIC CO LTD (JP) 2026-01-07 EP disclosed
US-20250246685-A1 FLAME-RETARDANT NON-AQUEOUS ELECTROLYTIC SOLUTION AND SECONDARY BATTERY USING SAME KYOTO UNIVERSITY (JP) 2025-07-31 US disclosed
WO-2025120994-A1 SECONDARY BATTERY NON-AQUEOUS ELECTROLYTE AND SECONDARY BATTERY PROVIDED WITH SAME ステラケミファ株式会社 2025-06-12 WO disclosed
EP-3689973-B1 MOLDED ARTICLE FURUKAWA ELECTRIC CO LTD (JP) 2025-06-11 EP disclosed
CN-120000803-A Brush-like structure polypeptide drug delivery system and preparation method and application thereof 中国科学院杭州医学研究所 2025-05-16 CN disclosed
WO-2025095088-A1 NON-AQUEOUS ELECTROLYTE SOLUTION FOR SECONDARY BATTERY, AND SECONDARY BATTERY PROVIDED WITH SAID SOLUTION ステラケミファ株式会社 2025-05-08 WO disclosed
WO-2008022309-A2 POLYCONJUGATES FOR IN VIVO DELIVERY OF POLYNUCLEOTIDES F. HOFFMANN-LA ROCHE AG (US) 2008-02-21 WO disclosed
US-20070036865-A1 Endosomolytic Polymers MIRUS BIO CORPORATION (US) 2007-02-15 US disclosed
US-20060122096-A1 Reversible modification of amine-containing compounds Arrowhead Madison Inc. 2006-06-08 US disclosed
US-7019113-B2 Reversible modification of membrane interaction MIRUS BIO CORPORATION (US) 2006-03-28 US disclosed
US-20050250683-A9 Reversible modification of membrane interaction Arrowhead Madison Inc. 2005-11-10 US disclosed
EP-1506218-A2 REVERSIBLE MODIFICATION OF MEMBRANE INTERACTION Mirus Corporation (US) 2005-02-16 EP disclosed
WO-2003100081-A2 BIOLOGICALLY ACTIVE MALEAMIC ACID DERIVATIVES WITH LABILE AMIDE BONDS MIRUS CORPORATION (US) 2003-12-04 WO disclosed
US-20030220264-A1 Reversible modification of membrane interaction ROZEMA DAVID B (US) 2003-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122096-A1 Reversible modification of amine-containing compounds BRDT, AADAC, HDAC10 CDC25A 735/4885CDC25B 538/4885CDC25C 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.